189 related articles for article (PubMed ID: 10882281)
21. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis.
Fjaellegaard K; Koefod Petersen J; Reuter S; Malene Fischer B; Gerke O; Porcel JM; Frost Clementsen P; Laursen CB; Bhatnagar R; Bodtger U
Lung Cancer; 2021 Dec; 162():106-118. PubMed ID: 34775214
[TBL] [Abstract][Full Text] [Related]
22. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
[TBL] [Abstract][Full Text] [Related]
23. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
[TBL] [Abstract][Full Text] [Related]
24. Can PET/CT be used more effectively in pleural effusion evaluation?
Simsek FS; Yuksel D; Yaylali O; Aslan HS; Kılıçarslan E; Bir F; Arslan M; Can FE; Ugurlu E
Jpn J Radiol; 2021 Dec; 39(12):1186-1194. PubMed ID: 34165683
[TBL] [Abstract][Full Text] [Related]
25. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
[TBL] [Abstract][Full Text] [Related]
26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
27. Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer.
Alkhawaldeh K; Biersack HJ; Henke A; Ezziddin S
Clin Nucl Med; 2011 Jun; 36(6):423-8. PubMed ID: 21552017
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET imaging in assessing exudative pleural effusions.
Duysinx BC; Larock MP; Nguyen D; Corhay JL; Bury T; Hustinx R; Louis R
Nucl Med Commun; 2006 Dec; 27(12):971-6. PubMed ID: 17088683
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET in staging lung cancer: how does it change the algorithm?
Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
[TBL] [Abstract][Full Text] [Related]
30. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.
Stokkel MP; Bakker PF; Heine R; Schlösser NJ; Lammers JW; Van Rijk PP
Nucl Med Commun; 1999 Nov; 20(11):1001-7. PubMed ID: 10572909
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
Nakajima R; Abe K; Sakai S
Medicine (Baltimore); 2015 Jul; 94(29):e1010. PubMed ID: 26200610
[TBL] [Abstract][Full Text] [Related]
33. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
34. Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031.
McCarten KM; Metzger ML; Drachtman RA; Pei Q; Friedman DL; Schwartz CL; Kelly KM
Pediatr Radiol; 2018 Nov; 48(12):1736-1744. PubMed ID: 30014200
[TBL] [Abstract][Full Text] [Related]
35. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
36. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
37. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Bruzzi JF; Truong MT; Marom EM; Mawlawi O; Podoloff DA; Macapinlac HA; Munden RF
AJR Am J Roentgenol; 2006 Oct; 187(4):1116-23. PubMed ID: 16985164
[TBL] [Abstract][Full Text] [Related]
38. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
[TBL] [Abstract][Full Text] [Related]
39. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
